Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Pocket-sized population threat
May 18, 2026
The Financial Times took a deep dive into why populations around the world continue to be on the decline. The publication cited new University of Cincinnati research as part of the investigation that looks at the fall of fertility in the digital era.
UC finds integrating substance use disorder treatment into clinic-based internal medicine expands access to care
May 18, 2026
A University of Cincinnati primary care teaching clinic integrates substance use disorder treatment into resident training, expanding access to addiction care and boosting physician confidence.
A jolly good trip: Bearcats take on London for fragrance company
May 18, 2026
Six NEXT Innovation Scholars at the University of Cincinnati traveled to London to transform field research into actionable recommendations for British luxury bath, body and fragrance brand Molton Brown.